David Howton Sells 18,894 Shares of Solid Biosciences (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB) COO David Howton sold 18,894 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total transaction of $121,677.36. Following the completion of the sale, the chief operating officer owned 97,859 shares in the company, valued at approximately $630,211.96. The trade was a 16.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Solid Biosciences Price Performance

NASDAQ:SLDB opened at $6.52 on Friday. The company has a market cap of $507.97 million, a price-to-earnings ratio of -2.62 and a beta of 2.67. Solid Biosciences Inc. has a 1 year low of $2.41 and a 1 year high of $7.37. The stock’s 50 day simple moving average is $5.84 and its two-hundred day simple moving average is $5.71.

Institutional Investors Weigh In On Solid Biosciences

Hedge funds have recently modified their holdings of the company. UBS Group AG boosted its position in shares of Solid Biosciences by 25.9% during the 4th quarter. UBS Group AG now owns 911,409 shares of the company’s stock worth $5,140,000 after purchasing an additional 187,264 shares during the period. SG Americas Securities LLC purchased a new position in shares of Solid Biosciences in the 4th quarter valued at $118,000. CIBC Bancorp USA Inc. acquired a new position in Solid Biosciences in the third quarter valued at $228,000. Armistice Capital LLC boosted its holdings in shares of Solid Biosciences by 134.0% in the third quarter. Armistice Capital LLC now owns 936,000 shares of the company’s stock valued at $5,775,000 after acquiring an additional 536,000 shares during the period. Finally, Alyeska Investment Group L.P. increased its position in Solid Biosciences by 2.6% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,682,805 shares of the company’s stock valued at $10,383,000 after acquiring an additional 41,984 shares during the period. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Analyst Ratings Changes

SLDB has been the subject of several recent research reports. Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Solid Biosciences in a report on Wednesday, January 14th. Barclays set a $9.00 price target on Solid Biosciences and gave the company an “overweight” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. reduced their price objective on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Citigroup reiterated a “market outperform” rating on shares of Solid Biosciences in a research note on Wednesday, December 17th. Finally, Wall Street Zen downgraded Solid Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, October 19th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.70.

Key Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.